Cyclin-dependent kinase (cdk) 4 inhibitor (IC50
= 0.2 μ
M at cdk4/cyclin D1). Displays > 500-fold selectivity over cdk2 (IC50
> 100 μ
M for cdc2/cyclin A, cdk2/cyclin A and cdk2/cyclin E).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Kubo et al.
Clin.Cancer Res., 1999;5:4279
Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes et al.